Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma

Matthew Frigault • 10 Dec 2023
ASH 2023
Multiple Myeloma CAR-T CART-ddBCMA

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, presents follow-up data from a Phase I trial (NCT04155749) investigating an autologous anti-BCMA CAR T-cell therapy in patients with relapsed/refractory (R/R) multiple myeloma (MM). With a median follow-up of 26.5 months, the study shows a 100% overall response rate (ORR) and median progression-free survival (PFS) not yet reached, even for higher-risk patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Matthew Frigault

0:58
Itacitinib for the prevention of immune effector cell therapy–associated CRS
Matthew Frigault • 12 Dec 2023
Prophylaxis and management of CRS & ICANS
Bianca Santomasso et al. • 14 Apr 2023
Rapid CAR manufacture
Caron Jacobson et al. • 14 Apr 2023
0:29
ASCO 2022: ZUMA-2, BCMA-targeting BiTEs & novel CARs in myeloma
Matthew Frigault • 3 Jun 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals